The Pfizer Clinical Research Unit (PCRU) in Brussels is seeking healthy participants for a clinical trial of a study drug for the treatment of a certain type of breast cancer.

This study will evaluate the experimental drug alone or after taking another drug that is approved for sale in Belgium.

Who may participate

his study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. 

You may not take part in this study if: 
 

  • You are outside of the limits for this study of age (18-60 years ) or weight (more than 45 kg), or Body Mass Index (16-32 kg/m2). 
  • If you are pregnant, breastfeeding or a woman of childbearing potential, or a fertile male participant who is unwilling or unable to use highly effective methods of contraception for the duration of the study and for at least 103 days after the last dose of study intervention. 

 

There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process.  

Condition

Healthy

Age

18 - 60 years old

Sex

Male/female without childbearing potential

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium.   

The study will last for about 125 days. You will stay in the PCRU for 2 treatment periods, comprised of a total of 31 days and 29 nights.  

  • Period 1: 9 days and 8 nights (admission to Day 8) 
  • Period 2: 22 days and 21 nights (Admission to Day 21).  

The 2 treatment periods will be separated by an interval of at least 14 days. 

You will be screened within 28 days prior to the first dose of study intervention. 

Throughout the study, staff will closely monitor your health status and collect data. 

You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people. 

View calendar

How long is the study?

125 days

Compensation

Up to € 8.240 plus travel fees

Long-term follow-up

A follow-up call at the end of the study